p38 in chronic myelogenous leukemia: a target and a possible biomarker

Leuk Lymphoma. 2009 Dec;50(12):1909-10. doi: 10.3109/10428190903404272.
No abstract available

Publication types

  • Comment

MeSH terms

  • Apoptosis / drug effects
  • Biomarkers, Tumor / metabolism
  • Cell Cycle / drug effects
  • Cell Proliferation / drug effects
  • Dasatinib
  • Drug Resistance, Neoplasm / drug effects
  • Drug Resistance, Neoplasm / genetics
  • Enzyme Activation / drug effects
  • Humans
  • Immunoblotting
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Mutation
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / pharmacology
  • Pyrimidines / pharmacology*
  • RNA Interference
  • Signal Transduction / drug effects*
  • Thiazoles / pharmacology*
  • p38 Mitogen-Activated Protein Kinases / genetics
  • p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

  • Biomarkers, Tumor
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • p38 Mitogen-Activated Protein Kinases
  • Dasatinib